Cancer therapy: Targeting mitochondria and other sub-cellular organelles

Current Pharmaceutical Design

Volumn 20, Issue 2, 2014, Pages 201-222

  Ubah, Obinna C ^a   Wallace, Heather M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Apoptosis; Cancer therapy; Endoplasmic reticulum; Golgi apparatus; Lysosome; MOMP; Polyamines; Proteasome; ROS; Warburg effect

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 2 METHOXYOESTRADIOL; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 [N' (GLUTATHIONYLACETYL)AMINO] PHENYLARSENOXIDE; A 385358; ADENINE NUCLEOTIDE TRANSLOCASE; ANTINEOPLASTIC AGENT; BETA LAPACHONE; BETULIC ACID; BORTEZOMIB; BROMOPYRUVIC ACID; BUTHIONINE SULFOXIMINE; CARFILZOMIB; DEOXYGLUCOSE; DICHLOROACETIC ACID; ELESCLOMOL; GADOLINIUM TEXAPHYRIN; GOSSYPOL; ISOSORBIDE; LONIDAMINE; MANGAFODIPIR; MENADIONE; NAVITOCLAX; OBATOCLAX; OBLIMERSEN; PEROXIREDOXIN 3; POLYAMINE DERIVATIVE; PROTEASOME INHIBITOR; RETINOID DERIVATIVE; SALINOSPORAMIDE A; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER CELL; CANCER THERAPY; CELL DEATH; CELL FUNCTION; CELL ORGANELLE; CELL STRUCTURE; DRUG TARGETING; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; GOLGI COMPLEX; HUMAN; LYSOSOME; MITOCHONDRIAL PERMEABILITY; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG DESIGN; HUMANS; LYSOSOMES; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; NEOPLASMS; ORGANELLES;

EID: 84892963544     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990031     Document Type: Review

References (296)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
2. Fulda S. Tumor resistance to apoptosis. Int J Cancer 2009; 124: 511-5.
3. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discovery 2010; 9: 447-64.
4. Maag RS, Hicks SW, Machamer CE. Death from within: apoptosis and secretory pathway. Curr Opin Cell Biol 2003; 15: 456-61.
5. Waxman L, Fagan JM, Goldberg AL. Demonstration of two distinct high molecular weight proteases in rabbit reticulocytes, one of which degrades ubiquitin conjugates. J Biol Chem 1987; 262: 2451-7.
6. Adams J. The proteasome: a suitable antineoplastic target. Nature Reviews 2004; 4: 349-60.
7. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994; 79: 13-21.
8. Jäättelä M. Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene 2004; 23: 2746-56.
9. Ferrin F, Linares CI, Muntane J. Mitochondrial drug targets in cell death and cancer. Curr Pharm Des 2011; 17: 2002-16.
10. Serviddio G, Ronmano AD, Cassano T, Bellanti F, Altomare E, Vendemial G. Principles and therapeutic relevance for targeting mitochondria in aging and neurodegenerative diseases. Curr Pharm Des 2011; 17: 2036-55.
11. Victor VM, Rocha M, Banuls C, Bellod L, Hernandez-Mijares A. Mitochondrial dysfunction and targeted drugs: a focus on diabetes. Curr Pharm Des 2011; 17: 1986-2001.
12. Carreira RS, Lee P, Gottlieb RA. Mitochondrial therapeutics for cardioprotection. Curr Pharm Des 2011; 17: 2017-35.
13. Kroemer G, Galluzi L, Brenner C. Mitochondrial Membrane Permeabilization in Cell Death. Physiol Rev 2007; 87: 99-163.
14. Mitchell P, Moyle J. Evidence discriminating between the chemical and the chemiosmotic mechanisms of electron transport phosphorylation. Nature 1965; 208: 1205-6.
15. Mitchell P, Moyle J. Stoichiometry of proton translocation through the respiratory chain and adenosine triphosphatase systems of rat mitochondria. Nature 1965; 208: 147-51.
16. Navarro A, Boveris A. The mitochondrial energy transduction system and aging process. Am J Physiol Cell Physiol 2007; 292: C670-86.
17. Marchetti P, Castedo M, Susin SA et al. Mitochondrial permeability transition is central coordinating event of apoptosis. J Exp Med 1996; 184: 1155-60.
18. Zamzami N, Larochette N, Kroemer G. Mitochondrial permeability transition in apoptosis and necrosis. Cell Death Differ 2005; 12: 1478-80.
19. Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol 1998; 60: 619-42.
20. Zoratti M, Szabo I. The mitochondrial permeability transition. Biochim Biophys Acta 1995; 1241: 139-76.
21. Boveris A, Chance B. The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. Biochem J 1973; 156: 435-44.
22. Boveris A, Oshino N, Chance B. The cellular production of hydrogen peroxide. Biochem J 1972; 128: 617-30.
23. Yamada Y, Harashima H. Mitochondrial drug-delivery systems for macromolecule and their therapeutic application to mitochondrial diseases. Adv Drug Deliv Rev 2008; 60: 1439-62.
24. Augustin W, Wiswedel I, Noack H, Reinheckel T, Reichelt O. Role of endogenous and exogenous antioxidants in the defense against functional damage and lipid peroxidation in rat liver mitochondria. Mol Cell Biochem1997; 174: 199-205.
25. Fridovich I. Superoxide dismutases. Adv Enzymol Relat Areas Mol Biol 1974; 41: 35-97.
26. 2+: molecular determinants and functional consequences. Physiol Rev 2006; 86: 369-408.
27. 2+ microdomains to mitochondria. J Cell Biol 2002; 159: 613-624.
28. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-76.
29. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324-37.
30. Barczyk K, Kreuter M, Pryjma J. Serum cytochrome c indicates in vivo-apoptosis and it can serve as a prognostic marker during cancer therapy. Int J Cancer 2005; 114: 167-73.
31. Li LY, Luo X, Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 2001; 412: 95-99.
32. Antonsson B, Martinou, JC. The Bcl-2 protein family. Exp Cell Res 2000; 256: 50-7.
33. Pavlov EV, Priault M, Pietkiewicz D. A novel, high conductance channel of mitochondria linked to apoptosis in mammalian cells and Bax expression in yeast. J Cell Biol 2001; 155: 725-32.
34. Loeffler M, Kroemer G. The mitochondrion in cell death control: certainties and incognita. Exp Cell Res 2000; 256: 19-26.
35. Shimizu S, Matsuoka Y, Shinohara Y, Yoneda Y, Tsujimoto Y. Essential role of voltage-dependent anion channel in various forms of apoptosis in mammalian cells. J Cell Biol 2001; 152: 237-50.
36. Verrier F, Deniaud A, Lebras M. Dynamic evolution of adenine nucleotide translocase interactome during chemotherapy-induced apoptosis. Oncogene 2004; 23: 8049-64.
37. Kim R, Emi M, Tanabe M. Role of mitochondria as the gardens of cell death. Cancer Chemother Pharmacol 2006; 57: 545-53.
38. He L, Lemaster JJ. Regulated and unregulated mitochondrial permeability transition pores: a new paradigm of pore structure and function? FEBS Lett 2002; 512: 1-7.
39. Martinou JC, Desagher S, Antonsson B. Cytochrome c release from mitochondria: all or nothing. Nat Cell Biol 2000; 2: E41-3.
40. Lemasters JJ, Qian T, He L. Role of mitochondrial inner membrane permeabilisation in necrotic cell death, apoptosis, and autophagy. Antioxid Redox Signal 2002; 4: 769-81.
41. Finkel E. The mitochondrian: is it central to apoptosis? Science 2001; 292: 624-6.
42. Maddika S, Ande SR, Panigrahi S. Cell survival, cell death and cell cycle pathways are interconnected: Implications for cancer therapy. Drug Resistance Updates 2007; 10: 13-29.
43. Jacotot E, Costantini P, Laboureau E, Zamzami N, Susin SA, Kroemer G. Mitochondrial membrane permeabilisation during the apoptotic process. Ann N Y Acad Sci 1999; 887: 18-30.
44. Fulda S, Debatin KM. Apoptosis signalling pathways in anticancer therapy. Curr Cancer Ther Rev 2008; 4: 14-20.
45. Warburg O, Dickens F. The metabolism of tumors. Am J Med Sci 1931; 182: 123.
46. Warburg O, Wind F, Negelein E. The metabolism of tumor in the body. J Gen Physiol 1927; 8: 519-30.
47. Brandon M, Baldi PA, Wallace DC. Mitochondrial mutations in cancer. Oncogene 2006; 25: 4647-62.
48. Kroemer G. Mitochondria in cancer. Oncogene 2006; 25: 4630-2.
49. Singh KK, Ayyasamy V, Owens KM, Koul MS, Vujcic M. Mutations in mitochondrial DNA polymerase-gamma promote breast tumorigenesis. J Hum Genet 2009; 54: 516-24.
50. King A, Selak MA, Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 2006; 25: 4675-82.
51. Dang L, White DW, Gross S, et al. Cancer associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739-44.
52. Solani G, Sgarbi G, Baracca A. Oxidative phosphorylation in cancer cells. Biochim Biophys Acta 2011; 1807: 534-42.
53. Robey RB, Hay N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 2006; 25: 4683-96.
54. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25: 4633-46.
55. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004; 305: 626-9.
56. Cheng WC, Berman SB, Ivanovska I, et al. Mitochondrial factors with dual roles in death and survival. Oncogene 2006; 25: 4697-705.
57. Brenner C, Grimm S. The permeability transition pore complex in cancer cell death. Oncogene 2006; 25: 4744-56.
58. Cereghetti GM, Scorrano L. The many shapes of mitochondrial death. Oncogene 2006; 25: 4717-4724.
59. Moll UM, Marchenko N, Zhang XK. p53 and Nur77/TR3: Transcription factors that directly target mitochondria for cell death induction. Oncogene 2006; 25: 4725-43.
60. Fontenay M, Cathelin S, Amiot M, Gyan E, Solary E. Mitochondria in hematopoiesis and hematological diseases. Oncogene 2006; 25: 4757-67.
61. Shanmugam M, McBrayer SK, Rosen ST. Targeting the Warburg effect in haematological malignancies: from PET to therapy. Curr Opin Oncol 2009; 21: 531-6.
62. Mathupala SP, Ko YH, Pedersen PL. Hexokinase II: Cancer's Double-Edged Sword Acting as Both Facilitator and Gatekeeper of Malignancy when Bound to Mitochondria. Oncogene 2006; 25: 4777-86.
63. Zhivotovsky B, Kroemer G. Apoptosis and genomic instability. Nat Rev Mol Cell Biol 2004; 5: 752-62.
64. He Y, Wu J, Dressman DC, et al. Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. Nature 2010; 464: 610-4.
65. Polyak K, Li Y, Zhu H, et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet 1998; 20: 291-3.
66. Hung WY, Wu CW, Yin PH, et al. Somatic mutations in mitochondrial genome and their potential roles in the progression of human gastric cancer. Biochim Biophys Acta 2010; 1800: 264-70.
67. Kulawiec M, Owens KM, Singh KK. Cancer cell mitochondria confer apoptosis resistance and promote metastasis. Cancer Biol Ther 2009; 8: 1378-85.
68. Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta 2010; 1804: 433-9.
69. Shackelford RE, Kaufmann WK, Paules RS. Oxidative stress and cell cycle checkpoint function. Free Radic Biol Med 2000; 28: 1387-1404.
70. Bartsch H. Studies on biomarkers in cancer etiology and prevention: a summary and challenge of 20 years of interdisciplinary research. Mutat Res 2000; 462: 255-79.
71. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis 2000; 21: 361-70.
72. Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria in cancer cells: what is so special about them? Trends Cell Biol 2008; 18: 165-73.
73. Modica-Napolitano JS, Singh KK. Mitochondrial dysfunction in cancer. Mitochondrion 2004; 4: 755-62.
74. Bellance N, Lestienne P, Rossignol R. Mitochondria: from bioenergetics to the metabolic regulation of carcinogenesis. Front Biosci 2009; 14: 4015-34.
75. Baines CP, Kaiser RA, Sheiko T, Craigen WJ, Molkentin JD. Voltage-dependent anion channels are dispensable for mitochondrialdependent cell death. Nat Cell Biol 2007; 9: 550-5.
76. Galluzzi L, Kroemer G. Mitochondrial apoptosis without VDAC. Nat Cell Biol 2007; 9: 487-9.
77. Kokoszka JE, Waymire KG, Levy SE, et al. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature 2004; 427: 461-5.
78. Baines CP, Kaiser RA, Purcell NH, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 2005; 434: 658-62.
79. De Marchi U, Basso E, Szabo I, Zoratti M. Electrophysiological characterisation of the Cyclophilin D-deleted mitochondrial permeability transition pore. Mol Membr Biol 2006; 23: 521-30.
80. Tsujimoto Y, Shimizu S. Role of the mitochondrial membrane permeability transition in cell death. Apoptosis 2007; 12: 835-40.
81. Hu Z, Guo X, Yu Q, et al. Down-regulation of adenine nucleotide translocase 3 and its role in camptothecin-induced apoptosis in human hepatoma QGY7703 cells. FBS Lett 2009; 583: 383-8.
82. Lee J, Schriner SE, Wallace DC. Adenine nucleotide translocator 1 deficiency increases resistance of mouse brain and neurons to excitotoxic insults. Biochim Biophys Acta 2009; 1787: 364-70.
83. Jang JY, Choi Y, Jeon YK, Kim CW. Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo. Breast Cancer Res 2008; 10: R11.
84. Gallerne C, Touat Z, Chen ZX, et al. The fourth isoform of the adenine nucleotide translocator inhibits mitochondrial apoptosis in cancer cells. Int J Biochem Cell Biol 2010; 42: 623-9.
85. Schimmer AD, O'Brien S, Kantarjian H, et al. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14: 8295-301.
86. Belzacq AS, El Hamel C, Vieira HL, et al. Adenine nucleotide translocator mediates the mitochondrial membrane permeabilisation induced by Ionidamine, arsenite and CD437. Oncogene 2001; 20: 7579-87.
87. Shanmugam M, McBrayer SK, Rosen ST. Targeting the Warburg effect in haematological malignancies: from PET to Therapy. Curr Opin Oncol 2009; 21: 531-6.
88. Oudard S, Carpentier A, Banu, E, et al. Phase II study of Ionidamine and diazepam in the treatment of recurrent glioblastoma multiform. J Neurooncol 2003; 63: 81-6.
89. Dogliott L, Berruti A, Buniva T, et al. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomised trial. J Clin Oncol 1996; 14: 1165-72.
90. Berruti A, Bitossi R, Gorzegno G, et al. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. J Clin Oncol 2002; 20: 4150-9.
91. De Lena M, Lorusso V, Latorre A, et al. Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. Eur J Cancer 2001; 37: 364-8.
92. Mullauer FB, Kessler JH, Medema JP. Betulinic acid induces cytochrome c release and apoptosis in a Bax/Bak-independent, permeability transition pore dependent fashion. Apoptosis 2009; 14: 191-202.
93. Eiznhamer DA, Xu ZQ. Betulinic acid: a promising anti-cancer candidate. IDRugs 2004; 7: 359-73.
94. Fulda S, Debatin KM. Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroectodermal tumors. Med Pediatr Oncol 2000; 35: 616-8.
95. Fulda S, Scaffidi C, Susin S A, et al. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J Biol Chem 1998; 273: 33942-8.
96. Fulda S, Susin SA, Kroemer G, Debatin KM. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res 1998; 58: 4453-60.
97. Fulda S, Friesen C, Los M, et al. Betulinic acid triggers CD95 (APO-1/Fas)-and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 1997; 57: 4956-64.
98. Cadd VA, Hogg PJ, Harris AL, Feller SM. Molecular profiling of signalling proteins for effects induced by the anti-cancer compound GSAO with 400 antibodies. BMC Cancer 2006; 6: 155.
99. Dilda PJ, Ramsay EE, Corti A, Pompella A, Hogg PJ. Metabolism of the tumor angiogenesis inhibitor 4-(N-(S-Glutathionylacetyl) amino)phenylarsonous acid. J Biol Chem 2008; 283: 35428-34.
100. Don AS, Kisker O, Dilda P, et al. A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 2003; 3: 497-509.
101. Dilda PJ, Decollogne S, Weerakoon L, et al. Optimisation of the antitumour efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol. J Med Chem 2009; 52: 6209-16.
102. Park D, Chiu J, Perrone GG, Dilda PJ, Hogg PJ. The tumour metabolism inhibitors GSAO and PENAO react with cysteines 57 and 257 of mitochondrial adenine nucleotide translocase. Cancer Cell Intl 2012; 12: 11.
103. Slack JL, Rusiniak ME. Current issues in the management of acute promyelocytic leukemia. Ann Hematol 2000; 79: 227-38.
104. Notario B, Zamora M, Vinas O, Mampel T. All-trans-retinoic acid binds to and inhibits adenine nucleotide translocase and induces mitochondrial permeability transition. Mol Pharmacol 2003; 63: 224-31.
105. Magda D, Miller RA. Motexafin gadolinium: a novel redox active drug for cancer therapy. Semin Cancer Biol 2006; 16: 466-76.
106. Bradley KA, Pollack IF, Reid JM, et al. Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study. Neuro Oncol 2008; 10: 752-8.
107. Costantini P, Belzacq A, La Vieira H, et al. Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis. Oncogene 2000; 19: 307-14.
108. Bey EA, Bentle MS, Reinicke KE, et al. An NQO1-and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by lapachone. Proc Natl Acad Sci USA 2007; 104: 11832-7.
109. Maeda H, Ohizumi H, Segawa T, Kakehi Y, Ogawa O, Kakizuka A. Effective treatment of advanced solid tumours by the combination of arsenic trioxide and L-buthionine-sulfoximine. Cell Death Differ 2004; 11: 737-46.
110. Dragovich T, Mendelson D, Wong L, et al. Phase I trial of imexon in patients with advanced malignancy. J Clin Oncol 2007; 25: 1779-84.
111. Moulder S, Dhillon N, Ng C, et al. Phase I trial of imexon, a prooxidant, in combination with docetaxel for the treatment of pateints with advanced breast, non-small cell lung and prostate cancer. Invest New Drugs 2010; 28: 634-40.
112. Tuma RS. Reactive oxygen species may have antitumor activity in metastatic melanoma. J Natl Cancer Inst 2008; 100: 11-12.
113. Kirshner JR, He S, Balasubramanyam V, et al. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther 2008; 7: 2319-27.
114. Berkenblit A, Eder JP Jr., Ryan DP, et al. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin Cancer Res 2007; 13: 584-90.
115. O'Day S, Gonzalez R, Lawson D, et al. Phase II, randomised, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol 2009; 27: 5452-8.
116. Alexandre J, Nicco C, Chéreau C, et al. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst 2006; 98: 236-44.
117. Trachootham D, Zhou Y, Zhang H, et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by phenylethyl isothiocyanate. Cancer Cell 2006; 10: 241-52.
118. Xiao D, Lew KL, Zeng Y, et al. Phenethyl isothiocyanate-induced apoptosis in PC-3 human prostate cancer cells is mediated by reactive oxygen species-dependent disruption of the mitochondrial membrane potential. Carcinogenesis 2006; 27: 2223-34.
119. Xiao D, Powolny AA, Moura MB, et al. Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated death of human prostate cancer cells. J Biol Chem 2010; 285: 26558-69.
120. Chan DK, Miskimins WK. Metformin and phenethyl isothiocyanate combined treatment in vitro is cytotxic to ovarian cancer cultures. J Ovarian Res 2012; 5: 19.
121. Wood L, Leese MR, Leblond B, et al. Inhibition of superoxide dismutase by 2-methoxyoestradiol analogues and oestrogen derivatives: structure-activity relationships. Anticancer Drug Des 2001; 16: 209-15.
122. Cleveland JL, Kastan MB. Cancer: a radical approach to treatment. Nature 2000; 407: 309-11.
123. Matei D, Schilder J, Sutton G, et al. Activity of 2-methoxyoestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Gynecol Oncol 2009; 115: 90-6.
124. Tevaarwerk AJ, Holen KD, Alberti DB, et al. Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies. Clin Cancer Res 2009; 15: 1460-5.
125. 2-mediated oxidation and inactivation of phosphatises in growth factor signalling. Proc Natl Acad Sci USA 2008; 105: 7147-52.
126. Nonn L, Berggren M, Powis G. Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxidedependent apoptosis. Mol Cancer Res 2003; 1: 682-9.
127. Kropotov A, Gogvadze V, Shupliakov O, et al. Peroxiredoxin V is essential for protection against apoptosis in human lung carcinoma cells. Exp Cell Res 2006; 312: 2806-15.
128. Song IS, Kim HK, Jeong SH, et al. Mitochondrial peroxiredoxin III is apotential target for cancer therapy. Int J Mol Sci 2011; 12: 7163-85.
129. Chung YM, Yoo YD, Park JK, Kim YT, Kim HJ. Increased expression of peroxiredoxin II confers resistance to cisplatin. Anticancer Res 2001; 21: 1129-33.
130. Noh YH, Baek JY, Jeong W, Rhee SG, Chang TS. Sulfiredoxin transloaction into mitochondria play a crucial role in reducing hyperoxidised peroxiredoxin III. J Biol Chem 2009; 284: 8470-7.
131. Chipuk JE, Bouchier-Hayes L, Green DR. Mitochondrial outer membrane permeabilisation during apoptosis: the innocent bystander scenario. Cell Death Differ 2006; 13: 1396-402.
132. Gavathiotis E, Suzuki M, Davis ML, et al. BAX activation is initiated at a novel interaction site. Nature 2008; 455: 1076-81.
133. Bellot G, Cartron PF, Er E, et al. TOM22, a core component of the mitochondrial outer membrane protein translocation pore, is a mitochondrial receptor for the proapoptotic protein Bax. Cell Death Differ 2007; 14: 785-94.
134. Ross K, Rudel T, Kozjak-Pavlovic V. TOM-independent complex formation of Bax and Bak in mammalian mitochondria during TNFinduced apoptosis. Cell Death Differ 2009; 16: 697-707.
135. Rostovtseva TK, Boukari H, Antignani A, et al. Bax activates endophilin B1 oligomerisation and lipid membrane vesiculation. J Biol Chem 2009; 284: 34390-9.
136. Cipolat S, Rudka T, Hartmann D, et al. Mitochondrial rhomboid PARL regulates cytochrome c release during apoptosis via OPA 1-dependent cristae remodeling. Cell 2006; 126: 163-75.
137. Frezza C, Cipolat S, Martins de Brito O, et al. OPA 1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell 2006; 126: 177-89.
138. Vogler M, Dinsdale D, Dyer MJ, Cohen GM. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 2009; 16: 360-7.
139. Vogler M, Weber K, Dinsdale D, et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 2009; 16: 1030-9.
140. Oltersdorf T, Elmore, SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumors. Nature 2005; 435: 677-81.
141. Kang MH, Kang YH, Szymanska B, et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukaemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 2007; 110: 2057-66.
142. Tagscherer KE, Fassl A, Campos B, et al. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 2008; 27: 6646-56.
143. Kutuk O, Letai A. Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res 2008; 68: 7985-94.
144. Hann CL, Daniel VC, Sugar EA, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 2008; 68: 2321-8.
145. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-8.
146. Lynn A, Jones L. Gossypol and some other terpenoids, flavonoids, and phenols that affect quality of cottonseed protein. Am Oil Chemists Soc 1979; 56: 727-30.
147. Azmi AS, Mohammad RM. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol 2009; 218: 13-21.
148. Liu G, Kelly WK, Wilding G, Leopold L, Brill K, Somer B. An open-label, multicentre, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 2009; 15: 3172-219.
149. Kitada S, Kress CL, Krajewska M, Jia L, Pellecchia M, Reed JC. Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood 2008; 111: 3211-9.
150. Shoemaker AR, Oleksijew A, Bauch J, et al. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res 2006; 66: 8731-9.
151. Nguyen M, Marcellus RC, Roulston A, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007; 104: 19512-7.
152. Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY, Stewart AK. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 2007; 109: 5430-8.
153. O'Brien SM, Claxton DF, Crump M, et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009; 113: 299-305.
154. Schimmer A D, O'Brien S, Kantarjian H, et al. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14: 8295-301.
155. Parikh SA, Kantarjian H, Schimmer A, et al. Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clinical lymphoma, myeloma & leukemia 2010; 10: 285-9.
156. Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 2002; 12: 193-213.
157. Moulder SL, Symmans WF, Booser DJ, et al. Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res 2008; 14: 7909-16.
158. O'Brien S, Moore JO, Boyd TE, et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 1114-1120.
159. Pro B, Leber B, Smith M, et al. Phase II multicenter study of oblimersen sodium, a Bcl2 antisense oligonucleotide, in combination with rituximab in patients with recurrent Bcell nonHodgkin lymphoma. Br J Haematol 2008; 143: 355-60.
160. Chanan-Khan AA, Niesvizky R, Hohl RJ, et al. Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leuk Lymphoma 2009; 50: 559-65.
161. Rudin CM, Salgia R, Wang X, et al. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 2008; 26: 870-6.
162. Wang JL, Liu D, Zhang ZJ, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000; 97: 7124-9.
163. Manero F, Gautier F, Gallenne T, et al. The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res 2006; 66: 2757-64.
164. Oliver L, Mahé B, Gréé R, Vallette FM, Juin P. HA14-1, a small molecule inhibitor of Bcl-2, bypasses chemoresistance in leukaemia cells. Leuk Res 2007; 31: 859-63.
165. Wallace HM, Fraser AV, Hughes A. A perspective of polyamine metabolism. Biochem J 2003; 376: 1-14.
166. Gerner EW, Meyskens FL. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 2004; 4: 781-92.
167. Marton LJ, Pegg AE. Polyamines as targets for therapeutic intervention. Annu Rev Pharmacol Toxicol 1995; 35: 55-91.
168. Bergeron RJ, Neims AH, McManis JS, et al. Synthetic polyamine analogs as antineoplastics. J Med Chem 1988; 31: 1183-90.
169. Casero RA, Marton LJ. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Dis 2007; 6: 373-90.
170. Huang Y, Stewart TM, Wu Y, et al. Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin Cancer Res 2009; 15: 7217-28.
171. Xie SQ, Liu GC, Ma YF, et al. Synergistic antitumor effects of anthracenylmethyl homospermidine and alphadifluoromethylornithine on promyelocytic leukemia HL60 cells. Toxicol In vitro 2008; 22: 352-8.
172. Palmer A J, Ghani RA, Kaur N, Phanstiel O, Wallace HM. A putrescine-anthracene conjugate: a paradigm for selective drug delivery. Biochem J 2009; 424: 431-8.
173. Guppy M, Greiner E, Brand K. The role of the Crabtree effect and an endogenous fuel in the energy metabolism of resting and proliferating thymocytes. Eur J Biochem 1993; 212: 95-9.
174. DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 2007; 104: 19345-50.
175. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4: 891-9.
176. Ko YH, Smith BL, Wang Y, et al. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophysical Res Commun 2004; 324: 269-75.
177. Xu RH, Pelicano H, Zhou Y, et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005; 65: 613-21.
178. Vali M, Liapi E, Kowalski J, et al. Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer. J Vasc Interv Radiol 2007; 18: 95-101.
179. Airley RE, Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 2007; 53: 233-56.
180. Medina RA, Owen GI. Glucose transporters: expression, regulation and cancer. Biol Res 2002; 35: 9-26.
181. Matsushita K, Uchida K, Saigusa S, et al. Glycolysis inhibitors as a potential therapeutic option to treat aggressive neuroblastoma expressing GLUT1. J Pediatr Surg 2012; 47: 1323-30.
182. Xu RH, Pelicano H, Zhang H, Giles FJ, Keating MJ, Huang P. Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia 2005; 19: 2153-8.
183. Chiara F, Castellaro D, Marin O, et al. Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels. PLoS One 2008; 3: e1852.
184. Goldin N, Arzoine L, Heyfets A, et al. Methyl jasmonate binds to and detaches mitochondria-bound hexokinase. Oncogene 2008; 27: 4636-43.
185. Brown J. Effect of 2-deoxyglucose on carbohydrate metabolism: review of the literature and studies in the rat. Metabolism 1962; 11: 1098-112.
186. Kang HT, Hwang ES. 2-Deoxyglucose: an anticancer and antiviral therapeutic, but not anymore a low glucose mimetic. Life Sci 2006; 78: 1392-9.
187. Maher J, Krishan A, Lampidis T. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol 2004; 53: 116-22.
188. Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, Spitz DR. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res 2007; 67: 3364-70.
189. Singh D, Banerji AK, Dwarakanath BS, et al. Optimizing cancer radiotherapy with 2-deoxy-D-glucose. Strahlentherapie und Onkologie 2005; 181: 507-14.
190. Zhong D, Liu X, Schafer-Hales K, et al. 2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMPactivated protein kinase signalling activation or glycolysis inhibition. Mol Cancer Ther 2008; 7: 809-17.
191. + Channel Axis Is Suppressed in Cancer and Its Normalization Promotes Apoptosis and Inhibits Cancer Growth. Cancer cell 11: 37-51.
192. Stacpoole PW, Kerr DS, Barnes C, et al. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 2006; 117: 1519-1531.
193. Hatzivassiliou G, Zhao F, Bauer DE, et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005; 8: 311-21.
194. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB. ATP-citrate lyase links cellular metabolism to histone acetylation. Sci Signalling 2009; 324: 1076-80.
195. Brooks P, Fuertes G, Murray RZ, et al. Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. Biochem J 2000; 346: 155-61.
196. Elliott PJ, Ross JS. The proteasome: a new target for novel drug therapies. Am J Clin Pathol 2001; 116: 637-46.
197. Ahn K, Erlander M, Leturcq D, Peterson PA, Früh K, Yang Y. In vivo characterization of the proteasome regulator PA28. J Biol Chem 1996; 271: 18237-42.
198. Rechsteiner M, Realini C, Ustrell V. The proteasome activator 11 S REG (PA28) and class I antigen presentation. Biochem J 2000; 345: 1-15.
199. Lafarga M, Fernández R, Mayo I, Berciano MT, Castaño JG. Proteasome dynamics during cell cycle in rat Schwann cells. Glia 2002; 38: 313-28.
200. Drexler HC. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 1997; 94: 855-60.
201. Drexler HC, Risau W, Konerding MA. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 2000; 14: 65-77.
202. Rajkumar S V, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005; 23: 630-9.
203. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-22.
204. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. New Engl JMed 2003; 348: 2609-17.
205. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776-83.
206. Cusack JC. Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 2003; 29: 21-31.
207. Lenz HJ. Clinical update: Proteasome inhibitors in solid tumors. Cancer Treat Rev 2003; 29: 41-8.
208. Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007; 67: 6383-91.
209. Kuhn DJ, Chen Q, Voorhees P M, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007; 110: 3281-90.
210. Molineaux SM. Molecular pathways: targeting proteasomal protein degradation in cancer. Clin Cancer Res 2012; 18: 15-20.
211. Bross PF, Kane R, Farrell AT, et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 2004; 10: 3954-64.
212. Niesvizky R, Wang L, Orlowski RZ, et al. Phase Ib multicenter dose escalation study of carfilzomib plus lenalidomide and low dose dexamethasone (CRd) in relapsed and refractory multiple myeloma (MM). Blood 2009; 114: 128-9.
213. Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012; 120: 947-59.
214. Baritaki S, Berkers C, Bonavida B, et al. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets 2011; 11: 254-84.
215. Obaidat A, Weiss J, Wahlgren B, et al. Proteasome regulator marizomib (NPI-0052) exhibits prolonged inhibition, attenuated efflux, and greater cytotoxicity than its reversible analogs. J Pharmacol Exp Ther 2011; 337: 479-86.
216. Singh AV, Palladino MA, Lloyd GK, Potts BC, Chauhan D, Anderson KC. Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI0052 (marizomib) in a human plasmacytoma xenograft murine model. Br J Haematol 2010; 149: 550-9.
217. Kupperman E, Lee EC, Cao Y, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 2010; 70: 1970-80.
218. Chauhan D, Tian Z, Zhou B, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 2011; 17: 5311-21.
219. Chauhan D, Singh A V, Aujay M, et al. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 2010; 116: 4906-15.
220. Papadopoulos KP, Mendelson DS, Tolcher AW, Patnaik A, Burris HA, Rasco DW. A phase I, open-label, doseescalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors. J Clin Oncol 2011; 29.
221. Yoshida H. ER stress response, Peroxisome prioliferation, Mitochondrial unfolded protein response and Golgi stress response. Life 2009; 61: 871-9.
222. Brodsky JL. The protective and destructive roles played by molecular chaperones during ERAD (endoplasmic-reticulum-associated degradation). Biochem J 2007; 404: 353-63.
223. Malhotra JD, Kaufman RJ. The endoplasmic reticulum and the unfolded protein response. Semin Cell Dev Biol 2007 18: 716-31.
224. Yoshida H. ER stress and diseases. FEBS J 2007; 274: 630-58.
225. Wlodkowic D, Skommer J, McGuinness D, Hillier C, Darzynkiewicz Z. ER-Golgi network-a future target for anticancer therapy. Leuk Res 2009; 33: 1440-7.
226. Wang G, Yang ZQ, Zhang K. Endoplasmic reticulum stress response in cancer: molecular mechanism and therapeutic potential. Am J Transl Res 2010; 2: 65-74.
227. Lee AS. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res 2007; 67: 3496-9.
228. Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol 2003; 4: 552-65.
229. Scorrano L, Korsmeyer SJ. Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem Biophys Res Commun 2003; 304: 437-44.
230. Healy SJ, Gorman AM, Mousavi-Shafaei P, Gupta S, Samali A. Targeting the endoplasmic reticulum-stress response as an anticancer strategy. Eur J Pharmacol 2009; 625: 234-46.
231. Obeng EA, Carlson LM, Gutman DM, et al. Proteasome inhibitiors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107: 4907-16.
232. Davenport EL, Moore HE, Dunlop AS, et al. Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood 2007; 110: 2641-49.
233. Gills JJ, LoPiccolo J, Tsurutani J, et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clinical Cancer Res 2007; 13: 5183-94.
234. Pyrko P, Kardosh A, Wang W, Xiong W, Schönthal AH, Chen TC. HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res 2007; 67: 10920-28.
235. Kraus M, Malenke E, Gogel J, et al. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomibinduced apoptosis. Mol Cancer Ther 2008; 7: 1940-8.
236. Deng WG, Ruan KH, Du M, Saunders MA, Wu KK. Aspirin and salicylate bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its ATPase activity in human fibroblasts. FASEB J 15: 2463-70.
237. Ermakova SP, Kang BS, Choi BY, et al. Epigallocatechin Gallate Overcomes Resistance to Etoposide-Induced Cell Death by Targeting the Molecular Chaperone Glucose-Regulated Protein 78. Cancer Res 2006; 66: 9260-9.
238. Zhou Y, Lee AS. Mechanism for the suppression of the mammalian stress response by genistein, an anticancer phytoestrogen from soy. J Natl Cancer Inst 1998; 90: 381-8.
239. Park HR, Furihata K, Hayakawa Y, Shin-ya K. Versipelostatin, a novel GRP78/Bip molecular chaperone down-regulator of microbial origin. Tetrahedron Lett 2002; 43: 6941-5.
240. Umeda Y, Furihata K, Sakuda S, et al. Absolute structure of prunustatin A, a novel GRP78 molecular chaperone down-regulator. Organic Lett 2007; 9: 4239-42.
241. Park HR, Ryoo IJ, Choo SJ, et al. Glucose-deprived HT-29 human colon carcinoma cells are sensitive to verrucosidin as a GRP78 down-regulator. Toxicol 2007; 229: 253-61.
242. Hwang JH, Kim JY, Cha MR, et al. Etoposideresistant HT29 human colon carcinoma cells during glucose deprivation are sensitive to piericidin A, a GRP78 downregulator. J Cell Physiol 2008; 215: 243-50.
243. Choo SJ, Park HR, Ryoo IJ, et al. Deoxyverrucosidin, a novel GRP78/BiP down-regulator, produced by Penicillium sp. J Antibiot 2005; 58: 210-3.
244. Schönthal AH. (2012) Pharmacological targeting of endoplasmic reticulum stress signalling in cancer. Biochem Pharmacol 2012; 85: 653-66.
245. Yu DH, Macdonald J, Liu G, et al. Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy. PloS one 2008; 3: e3951.
246. Kim JY, Hwang JH, Cha MR, et al. Arctigenin blocks the unfolded protein response and shows therapeutic antitumor activity. J Cell Physiol 2010; 224: 33-40.
247. Ni M, Zhang Y, Lee AS. Beyond the endoplasmic reticulum: atypical GPR78 in cell viability, signalling and therapeutic targeting. Biochem J 2011; 434: 181-8.
248. Wallen E, Sellers RG, Peehl DM. Brefeldin A induces p53-independent apoptosis in primary cultures of human prostatic cancer cells. J Urol 2000; 164: 836-41.
249. Shao RG, Shimizu T, Pommier Y. Brefeldin A is a potent inducer of apoptosis in human cancer cells independently of p53. Exp Cell Res 1996; 227: 190-6.
250. Choi JH, Choi AY, Yoon H, et al. Baicalein protects HT22 murine hippocampal neuronal cells against endoplasmic reticulum stressinduced apoptosis through inhibition of reactive oxygen species production and CHOP induction. Exp Mol Med 2010; 42: 811-22.
251. Denmeade SR, Jakobsen CM, Janssen S, et al. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst 2003; 95: 990-1000.
252. Denmeade SR, Mhaka AM, Rosen DM, et al. Engineering a Prostate-Specific Membrane Antigen-Activated Tumor Endothelial Cell Prodrug for Cancer Therapy. Sci Transl Med 2012; 4: 140ra86-140ra86.
253. Suh DH, Kim MK, Kim HS, Chung HH, Song YS. Unfolded protein response to autophagy as a promising druggable target for anticancer therapy. Ann N Y Acad Sci 2012; 1271: 20-32.
254. Koki AT, Masferrer JL. Celecoxib: a selective COX-2 inhibitor with anticancer properties. Cancer Control 2002; 9: 28-35.
255. Schönthal AH. Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br J Cancer 2007; 97: 1465-8.
256. Dogne JM, Thiry A, Supuran CT. Carbonic anhydrase inhibition: insight into non-COX-2 pharmacological effect of some coxibs. Curr Pharm Des 2008; 14: 679-84.
257. Kardosh A, Golden EB, Pyrko P, et al. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2, 5-dimethyl-celecoxib. Cancer Res 2008; 68: 843-51.
258. Schönthal AH, Chen TC, Hofman FM, Louie SG, Petasis NA. Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opin Investig Drugs 2008; 17: 197-208.
259. Tseng PH, Lin HP, Zhu J, et al. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. Blood 2005; 105: 4021-7.
260. Tseng PH, Wang YC, Weng SC, et al. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Mol Pharmacol 2006; 70: 1534-41.
261. Weng SC, Kashida Y, Kulp SK, et al. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor. Mol Cancer Thera 2008; 7: 800-8.
262. Thomas S, Sharma N, Golden EB, et al. Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors. Cancer Lett 2012; 325: 63-71.
263. Briceno E, Calderon A, Sotelo J. Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. Surg Neurol 2007; 67: 388-91.
264. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 2004; 11: 448-57.
265. Janku F, McConkey DJ, Hong DS, Kurzrock R. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol 2011; 8: 528-39.
266. Solomon VR, Lee H. Chloroquine and its analogs; a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol 2009; 625: 220-33.
267. De Duve C. Lysosomes revisited. Eur J Biochem 1983; 137: 391-7.
268. Castino R, Démoz M, Isidoro C. Destination 'Lysosome': a target organelle for tumour cell killing? J Mol Recogn 2003; 16: 337-48.
269. Borgonovo B, Cocucci E, Racchetti G, Podini P, Bachi A, Meldolesi J. Regulated exocytosis: a novel, widely expressed system. Nat Cell Biol 2002; 4: 955-62.
270. Jaiswal JK, Andrews NW, Simon SM. Membrane proximal lysosomes are the major vesicles responsible for calciumdependent exocytosis in nonsecretory cells. J Cell Biol 25: 625-35.
271. Kisen GØ, Tessitore L, Costelli P, et al. Reduced autophagic activity in primary rat hepatocellular carcinoma and ascites hepatoma cells. Carcinogenesis 1993; 14: 2501-05.
272. Fehrenbacher N, Jäättelä M. Lysosomes as targets for cancer therapy. Cancer Res 65: 2993-5.
273. Reinheckel T, Deussing J, Roth W, Peters C. Towards specific functions of lysosomal cysteine peptidases: phenotypes of mice deficient for cathepsin B or cathepsin L. Biol Chem 2001; 382: 735-41.
274. Kos J, Lah TT. Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer. Oncol Rep 1998; 5: 1349-61.
275. Turk B, Turk D, Turk V. Lysosomal cysteine proteases: more than scavengers. Biochimica et Biophysica Acta 2000; 1477: 98-111.
276. Koblinski JE, Ahram M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta 2000; 291: 113-35.
277. Joyce JA, Baruch A, Chehade K, et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer cell 2004; 5: 443-53.
278. Lakka SS, Gondi CS, Yanamandra N, et al. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 2004; 23: 4681-9.
279. Cirman T, Orei K, Mazovec GD, et al. Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by multiple papain-like lysosomal cathepsins. J Biol Chem 2004; 279: 3578-87.
280. Mousavi SA, Brech A, Berg T, Kjeken R. Phosphoinositide 3-kinase regulates maturation of lysosomes in rat hepatocytes. Biochem J 2003; 372: 861-9.
281. Madge LA, Li JH, Choi J, Pober JS. Inhibition of phosphatidylinositol 3-kinase sensitises vascular endothelial cells to cytokineinitiated cathepsin-dependent apoptosis. J Biol Chem 2003; 278: 21295-306.
282. Nylandsted J, Gyrd-Hansen M, Danielewicz A, et al. Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J Exp Med 2004; 200: 425-35.
283. Zang Y, Beard RL, Chandraratna RA, Kang JX. Evidence of a lysosomal pathway for apoptosis induced by the synthetic retinoid CD437 in human leukemia HL-60 cells. Cell death and differentiation 2001; 8: 477-85.
284. Neuzil J, Zhao M, Ostermann G, et al. Alpha-tocopheryl succinate, an agent with in vivo anti-tumour activity, induces apoptosis by causing lysosomal instability. Biochem J 2002; 362: 709-15.
285. Salvayre R, Auge N, Benoist H, Negre-Salvayre A. Oxidized lowdensity lipoprotein-induced apoptosis. Biochimica et Biophysica Acta 2002; 1585: 213-21.
286. Biasutto L, Dong L-F, Zoratti M, Neuzil J. Mitochondrially targeted anti-cancer agents. Mitochondrion 2010; 10: 670-81.
287. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005; 4: 145-60.
288. Kale AA, Torchilin VP. Enhanced transfection of tumor cells in vivo using "Smart" pH-sensitive TAT-modified pegylated liposomes. J Drug Target 2007; 15: 538-45.
289. Mu L, Elbayoumi TA, Torchilin VP. Mixed micelles made of poly(ethylene glycol)-phosphatidylethanolamine conjugate and d-tocopheryl polyethylene glycol 1000 succinate as pharmaceutical nanocarriers for camtothecin. Int J Pharm 2005; 306: 142-9.
290. Weissig V, Cheng SM, D'Souza GG. Mitochondrial pharmaceutics. Mitochondrion 2004; 3: 229-44.
291. Wsissig V, Boddapati SV, Cheng SM, D'Souza GG. Liposomes and liposome-like vesicles for drug and DNA delivery to mitochondria. J Liposome Res 2006; 16: 249-64.
292. Boddapati SV, Tongcharoensirikul P, Hanson RN, D'Souza GG, Torchilin VP, Weissig V. Mitochondriotropic liposomes. J Liposome Res 2005; 15: 49-58.
293. Boddapati SV, D'Souza GG, Erdogan S, Torchilin VP, Weissig V. Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett 2008; 8: 2559-63.
294. Kogure K, Akita H, Harashima H. Multifunctional envelope-type nano device for non-viral gene delivery: concept and application of programmed packaging. J Control Release 2007; 122: 246-51.
295. Kogure K, Akita H, Yamada Y, Harashima H. Multifunctional envelope-type nano device (MEND) as a non-viral gene delivery system. Adv Drug Deliv Rev 2008; 60: 559-71.
296. Yamada Y, Harashima H. Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases. Adv Drug Del Rev 2008; 60: 1439-62.